Standard Lithium

Phase A — Understand the business

Lens 1 · Company Overview

Standard Lithium Ltd. is a Canadian-domiciled, Vancouver-headquartered, NYSE American / TSXV-listed (SLI) development-stage lithium company whose entire enterprise value rests on commercializing Direct Lithium Extraction (DLE) of lithium from Smackover Formation brines in the US Gulf Coast (Arkansas + East Texas). It is a foreign private issuer filing on Form 40-F under the US–Canada Multijurisdictional Disclosure System, reporting under IFRS, with an audit by PricewaterhouseCoopers LLP. It changed its fiscal year-end from June 30 to December 31 in November 2024, so "FY2025" = calendar year ended Dec 31 2025.

The business model in plain terms: SLI does not yet sell anything. It is a pre-revenue optionality vehicle that (a) acquires brine mineral leases, (b) proves a resource under NI 43-101, (c) runs feasibility studies, (d) operates a DLE demonstration plant as a technology proof, and (e) is now attempting to convert its flagship asset into a financed, constructed, producing operation via a joint venture. Value accretes through de-risking milestones (resource → PFS → DFS → permits → offtake → project finance → FID → construction → first production), each of which re-rates or de-rates the equity.

The assets (in order of maturity):

1. South West Arkansas (SWA) — the flagship, FID-stage. Held in Smackover Lithium, a JV 55% Standard Lithium / 45% Equinor, with SLI as operator. Definitive Feasibility Study filed Sep–Oct 2025; Phase 1 targets 22,500 tpa battery-quality lithium carbonate over a 20-year modeled life; full project ~45,000 tpa. FID expected 2026, first production 2028–2029.
2. East Texas / Franklin Project — appraisal-stage, same JV. Maiden inferred resource 2.159 Mt LCE at 668 mg/L, containing the highest reported lithium-in-brine grades in North America (up to 806 mg/L at Pine Forest 1). Still drilling appraisal wells and doing DLE testing; targets >100,000 tpa of lithium chemicals across multiple phases eventually.
3. Phase 1A / LANXESS South Plant — the original "first commercial plant," now de-prioritized. 5,400 tpa over 25 years, DFS filed 2023 at the LANXESS South Plant in Union County, AR; management has since shifted strategic attention to SWA and this project has effectively been shelved-in-place (no active financing/construction path disclosed).

Customers / suppliers / competitors. First and only binding offtake to date: Trafigura Trading LLC — 8,000 tpa of battery-quality Li2CO3 over 10 years, announced March 2026, price confidential. Key "supplier" of capital and credibility is Equinor (JV partner, deep balance sheet) and the US Department of Energy (a $225M grant, below). Competitors: other North American lithium developers/producers — Lithium Americas (Thacker Pass, clay), Piedmont/Sayona (hard rock), Albemarle & LANXESS-adjacent incumbents (Smackover brine), and the DLE cohort (E3 Lithium, Vulcan).

Contract structure / concentration. No take-or-pay revenue yet. The Trafigura deal is a volume commitment (8,000 tpa) at confidential pricing "structured to support financing" — i.e. likely floor/formula-linked, not fixed. This is a single-customer, single-asset concentration at the point of first cash flow.

Lens 2 · Supply Chain

Map, with named stakeholders along the chain:

Upstream (inputs → the company):

• Brine resource — Smackover Formation aquifer, SW Arkansas (Lafayette/Columbia Counties) + East Texas (Franklin, ~80,000-acre area, >46,000 acres leased).
• Brine access / host operations — historically LANXESS bromine operations at the South Plant supplied tail-brine for the demonstration/Phase-1A concept; TETRA Technologies holds adjacent brine leases and has a relationship with the JV. For SWA the JV drills its own production/injection wells.
• DLE technology / reagents — SLI's proprietary/licensed DLE process (sorbent-based); the specific sorbent supply chain is a single-point technical dependency the company treats as proprietary.
• EPC / engineering — Wood plc engaged for SWA well-field EPCM; FEED completed by the DFS engineering team; "last key construction contract" awarded ahead of FID.
• Capital — Equinor (45% JV equity), US DOE ($225M grant), export credit agencies (EXIM, Eksfin — expressions of interest for >$1B ECA-backed debt), public equity markets (the Oct-2025 $130M raise).

The company (midstream): Smackover Lithium JV builds and operates the DLE + lithium carbonate conversion plant → produces battery-quality lithium carbonate.

Downstream (company → end customer):

• Offtaker / trader: Trafigura (8,000 tpa, 10 yr) — a commodities trader, i.e. an intermediary rather than an end-user, which is telling: as of mid-2026 the JV has NOT signed a cathode/automaker directly.
• End market: cathode producers → battery cell makers → EV OEMs / grid storage. No direct automaker or cell-maker offtake disclosed yet.

Chokepoints / single-source dependencies:

1. DLE process at commercial scale is unproven for this specific brine/plant — the demonstration plant is a proof, not a commercial reference. This is the single largest technical chokepoint.
2. Equinor — losing the partner would strip 45% of the equity and most of the balance-sheet credibility that unlocks ECA debt.
3. The $225M DOE grant — finalized Jan 2025, but sits inside a politically contested federal funding environment (Lens 10).
4. Single flagship asset — until Franklin matures, SWA is effectively the whole company.

This lens is named-not-generic per skill requirement: LANXESS, TETRA, Wood plc, Equinor, EXIM, Eksfin, Trafigura, DOE OMESC are the actual chain stakeholders.

Lens 3 · Competitive Advantages (moats)

Honest read: for a pre-revenue developer, the "moat" is really a set of de-risking assets that lower the cost/probability of reaching production faster than peers — not a durable earnings moat.

Genuine advantages:

• Resource grade. SWA is described as "North America's highest-grade reported lithium brine reserve"; Franklin holds the highest reported NA in-brine grades (up to 806 mg/L). Higher grade → lower unit cost → the DFS $4,516/t cash cost sits in the lower half of the global cost curve, which is the one thing that matters in a $10k/t lithium world.
• Jurisdiction. US Gulf Coast — domestic critical-mineral supply, existing Smackover oil-and-gas/brine infrastructure and skilled labor, and federal tailwinds (fast-track permitting, DOE grant, "America First" critical-minerals policy).
• Partner + capital stack. Equinor's 45% and technical heft, plus a $225M DOE grant and ECA interest in >$1B of debt, is a materially stronger financing position than most single-asset developers.
• Permitting progress. NEPA review concluded with a Finding of No Significant Impact; "no further federal reviews expected to take FID". Permit de-risking is real and hard to replicate quickly.

Weak / absent moats:

• DLE is not proprietary enough to be a moat. Multiple players (E3, Vulcan, ExxonMobil, Albemarle's own DLE) are pursuing Smackover/brine DLE. First-mover on permits ≠ IP lock.
• No brand, no switching costs, no network effects — it sells a fungible chemical commodity to a trader.
• Bargaining power is weak. As a pre-production developer needing capital and a first offtake, SLI needed Trafigura more than Trafigura needed it (confidential pricing "structured to support financing" = the financier's terms, not the seller's).

Verdict on the moat: the advantage is grade + jurisdiction + a funded, permitted, partnered head-start — a time-and-cost advantage, not a monopoly. It is real but perishable, and it only converts to value if lithium prices recover.

Lens 4 · Segments

segments.csv is empty — correct, because SLI is pre-revenue and has no reportable revenue segments. There is no revenue, EBITDA, or earnings to break out by product or geography. Reporting is a single development-stage entity with G&A + demonstration-plant R&D as its only P&L lines.

The meaningful "segmentation" is therefore by asset/project and by JV interest:

Trend: strategic weight has decisively shifted to SWA (bigger, higher-grade, DOE-funded, Equinor-partnered) away from the smaller LANXESS Phase-1A concept over 2024–2026. Franklin is the long-dated call option on top.

---

Phase B — Measure performance

Lens 5 · Latest "Result" (project milestones, not an earnings print)

There is no earnings beat/miss to analyze — SLI is pre-revenue. The Q1-2026 (quarter ended March 31 2026) 6-K reported a net loss of $2.7M (vs $1.6M prior-year quarter), driven by G&A + higher demonstration-plant R&D/maintenance costs, partly offset by a $2.2M non-cash FX gain on higher USD cash balances. The loss is immaterial as an "earnings" signal — the real "result" is the milestone tape:

Milestones that de-risked the equity (2025→2026):

• DFS filed for SWA (Sep–Oct 2025): pre-tax NPV $1.7B, IRR 20.2% @ 8% discount and $22,400/t Li2CO3 (Fastmarkets 20-yr forward avg); capex $1.45B; cash opex $4,516/t, all-in $5,924/t; 447,000 t Proven Reserves LCE over 20 yr. Principal recommendation: ready for FID.
• DOE $225M grant finalized/closed (Jan 16 2025).
• NEPA concluded with Finding of No Significant Impact; no further federal reviews to take FID.
• First binding offtake — Trafigura, 8,000 tpa × 10 yr (Mar 2026).
• Project-finance package taking shape: seeking up to $1.1B senior secured limited-recourse ECA-backed project debt (EXIM, Eksfin expressions of interest for >$1B) on top of the DOE grant + SLI/Equinor equity.
• Last key construction contract awarded ahead of FID; Wood plc engaged for well-field EPCM.

Balance-sheet flags: cash $141.0M, working capital $139.5M, no term or revolving debt as of Mar 31 2026. Funded by an Oct-2025 $130M follow-on (29,885,057 shares at $4.35). 239,705,571 shares outstanding as of Dec 31 2025.

The unusual-vs-history flag: the first-production date slipped — the Sep-2025 DFS release said first production 2028; the Q1-2026 call says 2029. On a pre-revenue developer, timeline slippage is the single most important negative "result," because NPV is discount-rate-sensitive and every year of delay is a year of dilution.

Lens 6 · Earnings Calls (sentiment trend)

transcripts/ is empty, so this is ``-sourced from Q1-2026 call coverage and prior releases.

Management focus (Q1-2026 call): singularly on closing the SWA project-finance package and offtake book to reach FID — "we expect to provide multiple updates in the coming months as we seek to conclude our ongoing project financing and customer offtake processes... and approve FID before beginning construction at SWA in 2026" (CEO David Park).

Tone shift over time (qualitative, ):

• 2023–early 2024 (Mintak era): narrative was about proving DLE and the LANXESS Phase-1A "first commercial plant."
• Mid-2024 → 2025 (Park era): pivot to SWA as the flagship; tone became execution/financing-oriented ("conclude financing," "approve FID") rather than discovery-oriented.
• 2025→2026: increasingly milestone-checklist language (DFS ✓, DOE ✓, NEPA ✓, first offtake ✓) — confident on de-risking, but every call pushes the FID/production goalposts slightly, which the market has learned to discount.

Recurring phrases: "highest-grade reported lithium brine," "ready to progress to FID," "strategic partner Equinor," "America's critical mineral supply chain." Stopped saying: aggressive near-term LANXESS Phase-1A first-production dates.

Lens 7 · Comps (developer-peer valuation — EV/EBITDA is meaningless pre-revenue)

Multiples are `` with source/date or n/a. For pre-revenue developers, EV/Sales, EV/EBIT, P/E, dividend yield, and 5-yr avg ROE are all n/a (no revenue, no earnings, no dividend, negative equity returns). The honest comp set is by market cap and asset stage:

What the comp set reveals: SLI trades at the low end of the North American lithium-developer cohort on market cap despite arguably the most complete de-risking package (DFS + DOE grant + Equinor + permits + first offtake). The discount reflects (a) DLE execution risk, (b) the fact that only ~55% of SWA is SLI's, and (c) a lithium tape that has crushed the entire sector. EV is not cleanly computable here — SLI has $141M cash and ~no debt, so EV < market cap (roughly $0.85–0.9B), but the "real" enterprise value must eventually absorb its 55% share of a $1.45B capex build. Any EV/resource or P/NAV multiple I would quote is not independently sourced → n/a; the defensible statement is qualitative: SLI is cheap relative to peers on de-risking-per-dollar, expensive relative to its own near-term cash flows (there are none).

Lens 8 · Stock-Price Catalysts (moves >5% over ~5 years)

Mostly ``; the pattern is what matters.

The dominant driver is the lithium price, not company-specific news. SLI's all-time-high close was $12.37 on Oct 27 2021 at the peak of the lithium mania; the stock then fell −26.6% in 2024, tracking lithium carbonate's collapse from ~$68,100/t (2022) to ~$10,500/t (2025). It then rose +186.5% in 2025 on the DFS/DOE/permit de-risking and a partial lithium-sentiment thaw, with a 52-week high of $6.40.

Company-specific >5% movers:

• Equinor JV / investment (2024) — a strategic-validation pop.
• DOE $225M grant finalization (Jan 2025) — up.
• Oct-2025 $130M dilutive raise at $4.35 — negative reaction (shares fell on dilution); an earlier 2025 raise + ~23% dilution reportedly drove a ~26% single-episode plunge.
• SWA DFS positive results (Sep–Oct 2025) — up.
• Trafigura first offtake (Mar 2026) — modest positive.

What the market actually reacts to (the pattern):

1. Lithium price / sector sentiment — the biggest single factor by far. SLI is a high-beta lithium call.
2. Dilution events — reliably negative, because the path to a $1.45B build implies more equity.
3. De-risking milestones (DOE, DFS, permits, offtake) — positive but increasingly expected, so each one moves the stock less than the last. The tell: a pre-revenue single-asset developer trades as a leveraged proxy on the lithium price plus a dilution-discount, with idiosyncratic milestones as second-order.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO — David Park (since Sep 1 2024). Ex-Koch: ~28 years across Koch entities, most recently President, Koch Strategic Platforms. He was the strategic advisor who helped secure Equinor as partner before taking the seat. Track record: heavy energy/industrial capital-allocation and strategic-partnership pedigree — exactly the profile you want to take a project from DFS to financed FID, and a notable upgrade in institutional heft for a former junior explorer. Skin in the game and personal ownership: n/a (insider-transactions data not on the shelf).
• President & COO — Dr. Andy Robinson. Long-tenured technical co-founder-era leader; continuity on the DLE science through the CEO transition.
• CFO — Salah Gamoudi. Signatory of the FY2025 40-F.
• Former CEO — Robert Mintak (retired Sep 2024, advisor through Aug 2025). Built SLI from junior explorer into a partnered developer over 7+ years; secured LANXESS, TETRA, Koch, and Equinor relationships.
• Audit committee financial expert: Claudia D'Orazio (independent); committee also Volker Berl, Jeffrey Barber, Paul Collins. Auditor: PwC LLP (PCAOB ID 271).

Capital-allocation history (candid): as a pre-revenue developer the "allocation" record is spend on studies + demonstration plant funded by serial equity issuance — inherently dilutive, no buybacks, no ROIC to judge (ROE is negative by construction). The strategic quality of the pivot to SWA and the Equinor/DOE capital-raising is the positive signal; the recurring dilution is the cost. The Koch→Equinor→DOE progression suggests management can attract tier-1 capital, which is the single most important managerial skill at this stage.

Red flags (management-specific): repeated timeline slippage (Phase-1A first-production dates missed; SWA first-production drifting 2028→2029); reliance on confidential-pricing offtake with a trader; founder-to-professional-manager transition just as the company enters its highest-execution-risk phase (a Koch operator is arguably the right archetype for the build phase, but the institutional memory of the DLE science sits with Robinson, not Park). Archetype: now a professional-manager / capital-markets-and-project operator, not a founder-explorer — appropriate for the FID-to-construction stage.

Lens 10 · Forensic Red Flags

Forensic-analyst read. The good news for a forensic analyst is also the limitation: there is almost no revenue-recognition, receivables, or margin manipulation surface because there is no revenue. The risks are development-stage risks.

• Going-concern / dilution. The recurring risk is capital adequacy: $141M cash against a 55% share of a $1.45B build means large future equity and/or debt financing is required — the DFS itself assumes ~$1.1B ECA debt + $225M DOE grant + JV equity. The realistic forensic flag is dilution risk, not fraud. IFRS development-stage accounting capitalizes vs expenses exploration/evaluation costs; watch how much SWA cost is capitalized to the balance sheet vs expensed (the actual figures are in Exhibit 99.3, not on the shelf → not independently verified here).
• Cash-flow vs earnings. Operating cash burn is modest and roughly tracks the reported loss (no large accrual divergence typical of a developer).
• Related parties. The Equinor JV and historical LANXESS/TETRA arrangements are the related-party surface — appear arm's-length and disclosed, but the JV structure means SLI's headline resource/NPV figures are 55%-attributable, not 100% — a framing risk if an investor reads project-level NPV as equity NPV.
• Non-GAAP / SBC. As a junior, stock-based compensation is a normal dilution vector; magnitude not independently sourced here (→ n/a from the shelf).
• Mineral-reserve reporting. Reserves are stated under NI 43-101 (Canadian standard), which the 40-F explicitly warns "may not qualify as such under SEC standards" and "may not be comparable" to US-company disclosure. A US investor should treat the reserve/NPV numbers as NI 43-101 constructs.
• Internal controls: management concluded disclosure controls and ICFR were effective as of Dec 31 2025; no auditor attestation on ICFR because SLI is an emerging-growth company (a disclosure gap, not a finding).

Regulatory findings (required sub-section):

• SEC Litigation Releases: None for Standard Lithium in the search period 2021-07-07 → 2026-07-07.
• SEC AAERs: None.
• Non-SEC enforcement (FTC/DOJ/FDA/CFPB/consent decree/fine): web search surfaced no material enforcement actions against Standard Lithium; the only "government" storyline is supportive (DOE grant, fast-track permitting) plus the sector-wide risk that the Trump administration is seeking an equity role in the largest US lithium project (Lithium Americas/Thacker Pass) — a read-across precedent that federal support can come with strings, not a finding against SLI.
• Item 3 (Legal Proceedings): the FY2025 40-F cover incorporates the AIF/MD&A "Risk Factors" by reference; no material litigation is surfaced in the on-shelf cover document. Item-3 detail lives in Exhibit 99.1 (AIF), not on the shelf → not independently verified here.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and the 40-F cover as of 2026-07-07. (Caveat: the full AIF Risk Factors / Legal Proceedings exhibit was not on the research shelf.)

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (project-NPV + cash runway, NOT an EPS line)

No EPS projection is appropriate — SLI will not have positive EPS until SWA produces (2028–2029 at the earliest) and even then earnings depend entirely on the realized lithium price and the JV split. Fabricating a three-year EPS path would violate provenance discipline. Instead, the scoreable projection is the value of the flagship asset and whether cash reaches FID:

SWA project value (the anchor):

• Pre-tax NPV8 $1.7B, IRR 20.2% @ $22,400/t Li2CO3, capex $1.45B, cash opex $4,516/t, all-in $5,924/t, 22,500 tpa × 20 yr.
• SLI's 55% share of NPV ≈ $0.94B pre-tax. This is pre-tax, project-level, at a $22.4k/t price — the equity claim is lower after tax, financing costs, and the discount for pre-FID execution risk.

Price sensitivity (the whole thesis): NPV scales roughly with (price − all-in cost). At the DFS $22,400/t, margin ≈ $16.5k/t. At spot ~$10.5k/t (2025), margin ≈ $4.6k/t — barely above cash cost, which would collapse the NPV toward or below zero. The project only "works" on a lithium-price recovery well above spot. This is the single most important sentence in the dossier.

Cash runway to FID: $141M cash, ~$11M/yr cash burn ( from ~$2.7M quarterly loss, mostly cash) → runway of years for corporate G&A, but grossly insufficient for construction. FID (2026) triggers the need to draw the DOE grant + close ~$1.1B ECA debt + fund SLI's ~55% equity share of ~$1.45B capex → material further financing (debt + likely equity) is required post-FID. Runway to FID = adequate; runway through construction = not funded, by design.

Base / bull / bear (asset-value framing):

• Base: FID reached H2-2026, ECA debt + DOE grant close, first production 2029; lithium recovers to ~$15–18k/t → SWA NPV realizable but SLI equity heavily diluted to fund its share → equity NPV materially below the $0.94B gross 55% figure.
• Bull: Lithium re-rates toward/through the DFS $22.4k/t, Franklin adds a second high-grade leg, Equinor/strategic funds most of the equity → the option pays off multiples.
• Bear: FID slips again or ECA debt doesn't close on acceptable terms; lithium stays sub-$12k/t → SWA NPV ≈ 0, further dilutive raises, equity re-rates down toward asset-option value.

Brier-scoreable binary (the honest forecast): "Standard Lithium / Smackover Lithium announces a positive Final Investment Decision (FID) for the SWA Project by 2026-12-31" — p ≈ 0.55. (Per the --watchlist rule, no forecast.ts create is run in this unattended sweep; logged here as the resolvable claim for a later human-gated pass.)

Lens 12 · Bull vs Bear

Bull case. The most complete de-risking package in the North American lithium-developer cohort sits on the market's lowest relative valuation. SWA has a filed DFS (NPV $1.7B, 20.2% IRR, the highest-grade reported NA brine reserve, lower-half-of-curve $4,516/t cash cost), a finalized $225M DOE grant, completed NEPA (FONSI, no further federal reviews to FID), a first binding offtake (Trafigura), an EPC contractor engaged, and a deep-pocketed 45% partner in Equinor whose presence unlocks >$1B of ECA-backed project debt. The company is fully funded to FID with $141M cash and no debt. If lithium simply mean-reverts toward its own 20-year forward curve, SLI is a call option that re-rates hard — and Franklin (highest-grade NA brine, >100k tpa target) is a second, free leg. Federal "America First" critical-minerals policy is a structural tailwind, and SWA is on the fast-track permitting list.

Bear case (2–3 permanent-impairment risks).

1. Lithium price stays broken. At ~$10.5k/t spot vs a $5,924/t all-in and a DFS built on $22,400/t, the NPV is a mirage — the project's economics are a levered bet on a price that may not return this cycle given the global oversupply from Chile/Argentina/Mali and decelerating EV growth. This can permanently impair the equity without any company-specific misstep.
2. DLE execution risk at scale. No commercial-scale reference plant for this brine exists; a cost/recovery/uptime shortfall vs DFS would blow up the unit economics. DLE is the whole technical thesis and it is unproven at 22,500 tpa.
3. Financing / dilution death-by-a-thousand-raises. SLI must fund its ~55% share of $1.45B capex; the $1.1B ECA debt is not closed; if it doesn't close on acceptable terms, or if lithium weakness shuts equity windows, the company faces severe dilution or a stalled build — the market has already punished every raise.

Pre-mortem (18 months out, thesis broke): FID slipped past 2026 again because the ECA debt package couldn't be sized without more offtake, and the offtake couldn't be signed at bankable prices because lithium stayed sub-$12k/t; SLI did another dilutive equity raise into a weak tape; the stock re-rated back toward $2–3 and the "de-risked" narrative was revealed to have been de-risked on everything except the two things that matter — price and project financing.

Are multiples too high? There are no earnings multiples. On P/NAV, the ~$1.0B market cap vs a ~$0.94B gross 55%-of-pre-tax-NPV looks inexpensive on paper — but that NPV is a $22.4k/t construct; haircut the price to spot and the "cheap" P/NAV inverts to expensive. The valuation is entirely a function of which lithium price you believe.

Contrarian view (what the market refuses to see): The bear consensus treats SLI as "just another busted lithium junior." What it under-weights is that the permitting + DOE + Equinor + DFS package is genuinely rare and largely irreversible — those milestones don't un-happen if lithium recovers. If you believe lithium is near a cyclical bottom, SLI is one of the highest-quality, most-optioned ways to own the recovery in a US-domestic, federally-favored jurisdiction. The market is pricing near-certainty of a bad lithium tape; the optionality on a good one is close to free.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• What structurally breaks the money-machine: it has no money-machine — it's a pre-revenue single-asset developer whose "value" is an NPV computed at a lithium price ~2x spot. Mark the DFS to spot and the equity is worth a fraction of today's price. The bull case is a spreadsheet, not a cash flow.
• Revenue concentration: first (and only) offtake is one trader, Trafigura, 8,000 tpa — a third of Phase-1 volume — at confidential pricing "structured to support financing." That phrasing is a tell that the financier, not the seller, set the terms; the JV took what it could get to make the debt bankable. No automaker or cathode-maker has signed.
• Why the moat is weaker than bulls think: DLE is a crowded field (ExxonMobil, Albemarle, E3, Vulcan all in Smackover/brine DLE). "Highest-grade reported brine" is a real edge, but grade doesn't build a plant — capital and proven process do, and both are unresolved.
• Most dangerous competitor bulls underestimate: ExxonMobil in the Smackover — infinite balance sheet, same formation, same DLE ambition. If Exxon scales DLE, SLI's cost/jurisdiction edge compresses and its offtake bargaining power evaporates.
• Worst capital-allocation reality: serial dilution — the share count has climbed via repeated raises (Oct-2025 $130M at $4.35 alone added ~30M shares), and the entire construction phase is still unfunded on the equity side. Every future raise into a weak tape transfers value from existing holders.
• Assumptions that must hold for today's price: (1) lithium recovers materially above ~$15k/t; (2) DLE hits DFS cost/recovery at commercial scale; (3) ~$1.1B ECA debt closes on acceptable terms; (4) SLI funds its 55% equity share without catastrophic dilution; (5) the DOE grant survives politically. All five must hold.
• If growth/price disappoints 20–30%: a 25% lithium-price haircut from the $22.4k/t DFS deck (to ~$16.8k/t) roughly halves the margin over all-in cost and takes a large bite out of the $1.7B NPV; a haircut to spot zeroes it.
• Single scenario that permanently impairs: structural lithium oversupply persisting through 2029 — SWA gets built into a $10k/t world with $5,924/t all-in costs and a debt load, producing thin-to-negative-margin lithium the JV must fund. Plausibility: moderate-to-material, given the current supply glut. That is the scenario that turns a "de-risked developer" into a distressed one.

Lens 14 · Management Questions (ordered by information value)

1. What is the fully-committed offtake book you need to size the ~$1.1B ECA debt facility, and how much of Phase-1's 22,500 tpa is contracted at bankable, floor-protected prices today vs the confidential Trafigura formula? (This most directly determines whether FID happens in 2026.)
2. Walk through SLI's ~55% equity funding requirement for the $1.45B build: how much fresh equity will Standard Lithium itself have to raise, at what assumed share price, and over what schedule? (The dilution question that defines equity return.)
3. At what realized lithium carbonate price does SWA's after-tax project IRR fall below your cost of capital, and what is your house view on where lithium trades in 2029–2035 vs the $22,400/t DFS deck?
4. What is the current status of the $1.1B ECA-backed debt (EXIM, Eksfin) — indicative term sheets, pricing, tenor, and conditions precedent — and what specifically is gating it from close?
5. What is the commercial-scale DLE performance risk: what lithium recovery %, uptime, and unit cost are you underwriting at 22,500 tpa, and what independent, at-scale reference do you have that the demonstration plant translates to commercial performance?
6. Is the $225M DOE grant fully insulated from clawback/renegotiation under the current administration, and are there any conditions (equity participation, domestic-content, milestone) attached that could change its value?
7. The first-production date moved from 2028 to 2029 — what slipped, and what is the critical-path item most likely to move it again?
8. Trafigura is a trader, not an end-user — what is the strategy and timeline to sign a cathode-maker or automaker directly, and does the Trafigura deal contain pricing that clears the DFS assumptions?
9. How should investors value the JV split in your headline numbers — is the $1.7B NPV project-level (55% to SLI), and what is the equity NPV to Standard Lithium after tax, financing, and dilution?
10. What is the capital-allocation priority between building SWA and advancing Franklin/East Texas — will Franklin compete with SWA for scarce capital, or is it strictly optional/later?
11. What is annual stock-based compensation and total G&A cash burn, and how does that scale as you move into construction?
12. What contingency does the $1.45B capex carry beyond the 12.3% Monte Carlo risked contingency, and what is your exposure to construction cost inflation and EPC contract structure (fixed vs reimbursable)?
13. What happens to Standard Lithium's 55% and operatorship if Equinor wants to increase its stake, exit, or if the JV needs a capital call SLI can't meet?
14. What is the plan for the parked Phase-1A / LANXESS South Plant asset — monetize, restart, or write down?
15. Beyond price and financing, what is the single risk on the horizon that you think the market is not pricing?

---